Baseline characteristics (N = 208)
| . | Number of patients . |
|---|---|
| Recipient age, median (min, max), y | 52 (19, 75) |
| Donor age, median (min, max), y | 38 (15, 73) |
| Male | 113 (54) |
| Race | |
| White | 123 (59) |
| Black | 80 (39) |
| Asian | 5 (2) |
| Recipient CMV status | |
| Positive | 161 (77) |
| Negative | 47 (23) |
| Disease type | |
| AML | 71 (34) |
| NHL/HD/CLL | 51 (25) |
| MDS/MPN/CML | 42 (20) |
| ALL | 36 (17) |
| MM | 5 (3) |
| AL | 3 (1) |
| DRI | |
| Low | 30 (14) |
| Intermediate | 100 (48) |
| High | 68 (33) |
| Very high | 9 (4) |
| N/A | 1 (1) |
| HCT-specific comorbidity index | |
| 0-2 | 113 (54) |
| ≥3 | 95 (46) |
| Stem cell source | |
| PBSC | 137 (66) |
| BM | 71 (34) |
| Conditioning intensity | |
| NMA | 122 (59) |
| MA | 86 (41) |
| Donor-recipient relationship | |
| Child | 99 (47) |
| Sibling/half sibling | 79 (38) |
| Parent | 29 (14) |
| Niece/nephew | 1 (1) |
| Year of transplant | |
| 2005-2010 | 49 (24) |
| 2011-2013 | 63 (30) |
| 2014-2016 | 96 (46) |
| Number of survivors | 105 |
| Survivor follow-up, median (min, max), mo | 65.4 (34.3, 157.2) |
| . | Number of patients . |
|---|---|
| Recipient age, median (min, max), y | 52 (19, 75) |
| Donor age, median (min, max), y | 38 (15, 73) |
| Male | 113 (54) |
| Race | |
| White | 123 (59) |
| Black | 80 (39) |
| Asian | 5 (2) |
| Recipient CMV status | |
| Positive | 161 (77) |
| Negative | 47 (23) |
| Disease type | |
| AML | 71 (34) |
| NHL/HD/CLL | 51 (25) |
| MDS/MPN/CML | 42 (20) |
| ALL | 36 (17) |
| MM | 5 (3) |
| AL | 3 (1) |
| DRI | |
| Low | 30 (14) |
| Intermediate | 100 (48) |
| High | 68 (33) |
| Very high | 9 (4) |
| N/A | 1 (1) |
| HCT-specific comorbidity index | |
| 0-2 | 113 (54) |
| ≥3 | 95 (46) |
| Stem cell source | |
| PBSC | 137 (66) |
| BM | 71 (34) |
| Conditioning intensity | |
| NMA | 122 (59) |
| MA | 86 (41) |
| Donor-recipient relationship | |
| Child | 99 (47) |
| Sibling/half sibling | 79 (38) |
| Parent | 29 (14) |
| Niece/nephew | 1 (1) |
| Year of transplant | |
| 2005-2010 | 49 (24) |
| 2011-2013 | 63 (30) |
| 2014-2016 | 96 (46) |
| Number of survivors | 105 |
| Survivor follow-up, median (min, max), mo | 65.4 (34.3, 157.2) |
Values are presented as the number (percentage) of patients unless otherwise indicated.
AL, acute leukemia unspecified; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; MM, multiple myeloma; N/A, not available; NHL, non-Hodgkin lymphoma.